LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on digital health and artificial intelligence solutions for Latin America, announced today that its Venezuelan subsidiary, LATAMEDAI VE, has entered into an agreement with DROGUERIAS LALA C.A. to develop AI-supported and automated software tools for pharmaceutical and laboratory workflows. The collaboration aims to design, develop, and test customized technology that could support pharmaceutical research, laboratory testing, quality control, documentation, operational coordination, and data analysis.
The proposed technology is expected to include features such as workflow automation, testing coordination, document management, data review, quality-control support, and predictive analytics. These tools are intended to help qualified personnel identify potential inconsistencies or operational issues earlier. The parties will begin by defining specific workflows, technical requirements, and a phased development process, while also establishing confidentiality and data-security protocols.
Dr. Kevin Rodan Levy, CEO of LataMed AI, stated, "This agreement represents an opportunity to apply our artificial intelligence and automation capabilities within complex pharmaceutical and laboratory environments. Our objective is to work with DROGUERIAS LALA C.A. to develop responsible technology that supports data analysis, documentation, testing coordination, quality-control processes, and other operational requirements while preserving appropriate professional oversight."
The collaboration is significant because it marks LataMed AI's expansion beyond patient-facing telemedicine services into enterprise pharmaceutical and laboratory applications. Management believes that if successful, the technology could be adapted for other organizations in Venezuela and Latin America, potentially improving efficiency and accuracy in critical healthcare processes.
However, the company emphasizes that the technology would serve as a decision-support and workflow-management tool, not a replacement for professional judgment. All pharmaceutical, scientific, and regulatory determinations would remain the responsibility of qualified professionals and regulatory authorities. The agreement does not guarantee implementation, revenue, or commercial deployment; it only establishes a framework for development and evaluation.
LataMed AI's broader strategy includes developing digital infrastructure and AI tools for healthcare providers, pharmacies, laboratories, and institutions. The company is also working on platforms like CardioAI, PulmoAI, and NeuroAI, which are designed to assist healthcare professionals in evaluating cardiovascular, pulmonary, and neurological health information, though these are still under development.
For more information, interested parties can visit the company's website at https://latamed.ai or review SEC filings at https://www.sec.gov.
